ライフサイエンスコーパス: included all patients who

1 Three consecutive cohorts that included all patients who began statin therapy during full dr

2 ere based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation fo

3 In this extension study, we included all patients who had been assigned everolimus during

4 This retrospective cohort included all patients who had HO bacteremia due to Escherichi

5 All analyses included all patients who had received at least one dose of t

6 The primary analysis included all patients who had received at least one fraction

7 The primary, modified intention-to-treat analysis included all patients who had testable serum samples before a

8 Our sample included all patients who received at least 2 outpatient BP m

9 ary endpoint was analysed using the per-protocol set, which included all patients who received at least one (partial or c

10 e done in the modified intention-to-treat population, which included all patients who received at least one day of treatm

11 Safety analyses included all patients who received at least one dose of denos

12 Safety analyses included all patients who received at least one dose of guade

13 ll safety analyses were done based on the safety set, which included all patients who received at least one dose of study

14 pressure and HbA1c measured in the full analysis set, which included all patients who received at least one dose of study

15 The safety population included all patients who received at least one dose of study

16 Activity and safety analyses included all patients who received at least one dose of study

17 The safety evaluable population included all patients who received at least one dose of study

18 The primary analyses included all patients who received at least one dose of study

19 d to one of the treatment groups, and the safety population included all patients who received at least one dose of study

20 analysis was by intention to treat, and the safety analysis included all patients who received at least one dose of study

21 Analysis included all patients who received at least one dose of study

22 Safety analyses included all patients who received at least one dose of study

23 The safety set included all patients who received at least one dose of study

24 Efficacy analysis included all patients who received at least one dose of study

25 Analyses included all patients who received at least one dose of study

26 re analysed by intention to treat and the safety population included all patients who received at least one dose of study

27 acy analysis was by intention to treat, and safety analysis included all patients who received at least one dose of study

28 The safety population included all patients who received at least one dose of study

29 The efficacy analysis included all patients who received at least one dose of the r

30 All analyses were done on the safety population, which included all patients who received at least one dose of vemur

31 e done per protocol for all patients who commenced drug and included all patients who received at least one dose of venet

32 The safety population included all patients who received at least one dose.

33 acy analysis was by intention to treat, and safety analysis included all patients who received at least one treatment wit

34 n the modified intention-to-treat population (n=800), which included all patients who received placebo or study drug and

35 The safety analysis population included all patients who received study treatment irrespecti

36 Safety analyses included all patients who received the study drug (ADS-5102 o

37 The safety analysis included all patients who took at least one dose of study med

38 In a Swedish nationwide population-based analysis, we included all patients who underwent cardiac surgery between 1

39 We included all patients who underwent coronary angiography for

40 Analysis was done by intention-to-treat analysis, which included all patients who underwent end-of-treatment biopsy.

41 Primary analysis included all patients who underwent one of the assigned proce

42 Swedish nationwide population-based cohort study that included all patients who underwent primary isolated CABG bet

43 o underwent one of the assigned procedures; safety analysis included all patients who underwent surgical intervention (ca

44 The final efficacy analysis included all patients who were compliant with study treatment

45 e done in the modified intention-to-treat population, which included all patients who were randomised and received at lea

46 yses were based on the intention-to-treat population, which included all patients who were randomly assigned and took at

47 mpliant retrospective study with waiver of informed consent included all patients who were referred for presurgical multi

48 dical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary